Gingerol Derivatives from the Rhizomes of Zingiber Officinale

Wang, Z.; Wang, K.-J.; Cheng, Chen-Shu; Li, N.; Wang, T.-M.; Di, Lijun

doi:10.5560/znb.2011.66b0740

Cited by 8 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In many cases, 6-SG has been reported to have better biological activities than 6-GN. In the plant, GNs co-occur with various analogues, including the gingerdiones (Wang et al, 2011a). The concentrations of 6-, 8-and 10-GN were found to diminish when fresh ginger was roasted, dried and charred, whereas the concentrations of 6-SG increased with the corresponding treatments .…”

Section: Introductionmentioning

confidence: 88%

Gingerols and shogaols: Important nutraceutical principles from ginger

et al. 2015

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 88%

Gingerols and shogaols: Important nutraceutical principles from ginger

et al. 2015

View full text Add to dashboard Cite

“…Among them, 8b-hydroxyisogermafurenolide (6) and 3-hydroxy-6-methylacetophe-none (8) were mentioned as by-products of synthetic reactions (Friedrich and Bohlmann, 1988;Kozhevnikova et al, 2003), but herein are reported for the first time as natural occurring compounds. Dehydro-6-gingerdione (9) was obtained from Zingiber officinale (Wang et al, 2011) but was isolated for the first time from Curcuma species in this work.…”

Section: Resultsmentioning

confidence: 99%

Acetylcholinesterase inhibitors and compounds promoting SIRT1 expression from Curcuma xanthorrhiza

Zhang

et al. 2015

Phytochemistry Letters

View full text Add to dashboard Cite

“…The RNAi technologies involve either transient gene-silencing by siRNA or stable inhibition by MDR1 shRNA-transfected on plasmid DNA of MDR cancer cells. Treatment with siRNA against MDR1 increases drug-mediated cytotoxicity in various MDR cancer cells such as paclitaxel in MDR1 ovarian cancer cells and doxorubicin in doxorubicin-resistant breast cancer cells [95]. In addition, siRNA was able to significant reduced size of doxorubicin-resistant xenograft in a mouse model [96].…”

Section: Microrna and Rna Interference (Rnai) Technologiesmentioning

confidence: 99%

Overcoming P-Glycoprotein-Mediated Doxorubicin Resistance

Jianmongkol¹

2021

Advances in Precision Medicine Oncology

View full text Add to dashboard Cite

Intracellular concentration of doxorubicin in target cancer cells is a major determinant of therapeutic success of doxorubicin-based regimens. As known, doxorubicin is a substrate of P-glycoprotein (P-gp), the drug efflux transporter in the ABC superfamily. High expression level of P-gp in cancer cells can prevent intracellular accumulation of doxorubicin up to its effective level, leading to doxorubicin resistance and treatment failure. Moreover, these P-gp-overexpressed cells display multi-drug resistance (MDR) phenotype. Regarding this, application of P-gp modulators (suppressor of P-gp activity and expression) is likely to reverse MDR and restore cell sensitivity to doxorubicin treatment. In searching for potential chemo-sensitizer against resistant cancer, a number of phytochemicals or dietary compounds have been studied extensively for their P-gp modulating effects. Furthermore, combination between doxorubicin and P-gp modulators (e.g., plant-derived compounds, siRNA) given through specific target delivery platforms have been an effective strategic approach for MDR reversal and restore doxorubicin effectiveness for cancer treatment.

show abstract

Gingerol Derivatives from the Rhizomes of Zingiber Officinale

Cited by 8 publications

References 0 publications

Gingerols and shogaols: Important nutraceutical principles from ginger

Gingerols and shogaols: Important nutraceutical principles from ginger

Acetylcholinesterase inhibitors and compounds promoting SIRT1 expression from Curcuma xanthorrhiza

Overcoming P-Glycoprotein-Mediated Doxorubicin Resistance

Contact Info

Product

Resources

About